CliffBio
biologic

mresvia

Respiratory Syncytial Virus Vaccine

Loss of exclusivityMay 2036FDA regulatory exclusivity expiry
CompanyModernaTX, Inc.

Drug detail

Brand namemresvia
Active ingredientRespiratory Syncytial Virus Vaccine
Strength50UG/.5ML
Dosage formFor Injection
RouteIntramuscular
ModalityBiologic
FDA approvalMay 2024
Marketing statusRx

More from ModernaTX, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

mresvia patent cliff — loss of exclusivity May 2036 | CliffBio